Verve Therapeutics (VERV) Earnings Date, Estimates & Call Transcripts $4.40 +0.17 (+3.89%) As of 11:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Verve Therapeutics Earnings Summary Verve Therapeutics posted Q1 2025 earnings on May 14, 2025, reporting an EPS of -$0.35, which beat analysts' consensus estimates of -$0.71 by $0.36. Quarterly revenue was reported to be $32.98 million, above the consensus estimate of $7.13 million. With a trailing EPS of -$2.11, Verve Therapeutics' earnings are expected to decrease next year, from ($2.49) to ($2.83) per share. Upcoming Q2 Earnings DateAug. 14Before Market OpensEstimatedConsensus EPS (May. 14) -$0.71 Actual EPS (May. 14) -$0.35 Beat By $0.36 Actual Revenue (May. 14) $32.98MQ1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)VERV Upcoming EarningsVerve Therapeutics' next earnings date is estimated for Thursday, August 14, 2025, based on past reporting schedules. Powered by Get Verve Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verve Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataVERV Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VERV Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Verve Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.66-$0.60-$0.63Q2 20252-$0.63-$0.63-$0.63Q3 20252-$0.73-$0.65-$0.69Q4 20252-$0.73-$0.66-$0.70 FY 2025 8 -$2.75 -$2.54 -$2.65 Q1 20262-$0.75-$0.61-$0.68Q2 20262-$0.73-$0.66-$0.70Q3 20262-$0.74-$0.68-$0.71Q4 20262-$0.75-$0.70-$0.73 Verve Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/14/2025(Estimated)--------5/14/2025Q1 2025-$0.71-$0.35+$0.36-$0.35$7.13M$32.98M2/27/2025Q4 2024-$0.72-$0.58+$0.14-$0.58$3.94M$13.08M11/5/2024Q3 2024-$0.70-$0.59+$0.11-$0.59$2.75M$6.87M8/8/2024Q2 2024-$0.68-$0.59+$0.09-$0.59$2.40M$6.70M5/8/2024Q1 2024-$0.70-$0.59+$0.11-$0.59$2.11M$5.70M2/27/2024Q4 2023-$0.83-$0.69+$0.14-$0.69$3.95M$5.14M11/7/2023Q3 2023-$0.90-$0.72+$0.18-$0.72$0.96M$3.10M8/10/2023Q2 2023-$0.90-$0.87+$0.03-$0.87$0.67M$2.10M Verve Therapeutics Earnings - Frequently Asked Questions When is Verve Therapeutics's earnings date? Verve Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 14th, 2025 based off last year's report dates. Learn more on VERV's earnings history. Did Verve Therapeutics beat their earnings estimates last quarter? In the previous quarter, Verve Therapeutics (NASDAQ:VERV) reported ($0.35) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.71) by $0.36. Learn more on analysts' earnings estimate vs. VERV's actual earnings. How much revenue does Verve Therapeutics generate each year? Verve Therapeutics (NASDAQ:VERV) has a recorded annual revenue of $59.61 million. How much profit does Verve Therapeutics generate each year? Verve Therapeutics (NASDAQ:VERV) has a recorded net income of -$200.07 million. VERV has generated -$2.11 earnings per share over the last four quarters. What is Verve Therapeutics's EPS forecast for next year? Verve Therapeutics's earnings are expected to decrease from ($2.49) per share to ($2.83) per share in the next year. More Earnings Resources from MarketBeat Related Companies Indivior Earnings Edgewise Therapeutics Earnings Janux Therapeutics Earnings ARS Pharmaceuticals Earnings Structure Therapeutics Earnings Travere Therapeutics Earnings 89bio Earnings Adaptive Biotechnologies Earnings Dyne Therapeutics Earnings Vera Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles CrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades This page (NASDAQ:VERV) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
